Skip to main content
. Author manuscript; available in PMC: 2017 Feb 22.
Published in final edited form as: J Gastrointest Cancer. 2015 Jun;46(2):161–165. doi: 10.1007/s12029-015-9690-7

Table 1.

Selected immunotherapies in clinical development for HCC

Drug Title NCT trial number Trial design Mechanism
Nivolumab Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC) With or Without Chronic Viral Hepatitis (Anti-PD-1 HCC) NCT01658878 Phase I Anti-PD-1 antibody
Tremelimumab Tremelimumab With Chemoembolization or Ablation for Liver Cancer NCT01853618 Phase I Anti-CTLA-4 antibody plus TACE or ablation
CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin’s Lymphoma, or Multiple Myeloma NCT01421524 Phase I expansion cohort Pleiotropic pathway modulation (IMID)
AMP-514 A Phase 1, Multi-Center, Open-label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMP-514 in Subjects With Advanced Solid Malignancies NCT02013804 Phase I Anti-PD-1 monoclonal antibody